A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
(SUMMIT Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new pill called JNJ-77242113 to see if it can better treat moderate-to-severe plaque psoriasis. The pill aims to calm the immune system, which helps reduce skin problems caused by psoriasis.
Will I have to stop taking my current medications?
You may need to stop taking certain medications before joining the trial. Specifically, if you are on medications targeting interleukin 17, interleukin 23, or tumor necrosis factor, you must stop them at least 12 weeks before starting the trial. Also, you should not take proton pump inhibitors within 1 week of starting the trial.
Research Team
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive JNJ-77242113 or placebo once daily for 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- JNJ-77242113
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Giacomo Salvadore
Janssen Research & Development, LLC
Chief Medical Officer since 2023
MD from the University of Rome, Tor Vergata
Ricardo Attar
Janssen Research & Development, LLC
Chief Executive Officer since 2008
PhD in Molecular Biology from the University of Buenos Aires